Dragan Popovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dragan Popovic has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Biljana Stankovic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia
2 shared publications - Branka Zukic
Group for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia
2 shared publications - Gordana Nikcevic
Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
2 shared publications - Nikola Kotur
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 Belgrade, Serbia
2 shared publications - Sanja Dragasevic
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
2 shared publications - Snezana Lukic
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
2 shared publications
Latest Publications
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES)
- p. 33
Farmakološki pristup lečenju funkcionalnog nadimanja
Ukoliko kod pacijenata sa funkcionalnim nadimanjem izostane pozitivan terapijski odgovor na nefarmakološku terapiju, promenu životnih navika i dijetu, pristupa se primeni farmakološke terapije. Farmakološka terapija je pre svega simptomatska, te se kao prvi lek najčešće upotrebljava simetikon u različitim dozama. Prema rezultatima pojedinih studija povoljan efekat na smanjenje nadimanja trbuha imaju i spazmolitici, kao što su pinaverin, mebeverin, otilonijum bromid, pepermintovo ulje, delujući na visceralnu hipersenzitivnost ovih pacijenata. Ukoliko kod pacijenata dominiraju simptomi opstipacije, u terapiji se primenjuju lekovi u zavisnosti od težine tegoba. Mogu se primeniti laksativi, ali i prokinetici, kao što je prukaloprid, ili sekretagogi, kao što su linaklotid, lubiproston, plekanatid. Akotiamid, inhibitor acetilholin esteraze i antagonista muskarinskih receptora, pokazao je pozitivno dejstvo na nadimanje, u studijama japanskih autora. Prema rezultatima studija veliki značaj u terapiji nadimanja i distenzije trbuha ima lokalni antibiotik rifaksimin. Rifaksimin ima minimalnu resorpciju iz kolona, pogodan je posebno kada se kod pacijenta postavi dijagnoza SIBO, dozira se tri puta 550mg, u trajanju od 14 dana. Uloga probiotika i dalje je intrigantna, obzirom da značajnu ulogu u patogenezi nadimanja ima izmenjena crevna mikrobiota. Sa druge strane nasumična primena probiotika mogla bi da poremeti sastav crevne mikrobiote, te se očekuje u budućnosti personalizovana primena probiotika na osnovu analize crevne mikrobiote svakog pacijenta pojedinačno. Do tada preporučuje se primena sojeva VSL#3, Lactobacillusa i Bifidobacteriuma. Primena neuromodulatora, takođe, ima veliki značaj i primenjuje se kada sve ostale terapije ne daju povoljne rezultate. Ovi lekovi uključuju inhibitore preuzimanja serotonina, triciklične antidepressive, buspirone. Na kraju treba napomenuti da se u terapiji nadimanja koriste i biljna terapija kao što je kurkumin, komorač, ali i lekovi tradicionalne kineske i japanske medicine.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES)
- p. 33
Farmakološki pristup lečenju funkcionalnog nadimanja
Ukoliko kod pacijenata sa funkcionalnim nadimanjem izostane pozitivan terapijski odgovor na nefarmakološku terapiju, promenu životnih navika i dijetu, pristupa se primeni farmakološke terapije. Farmakološka terapija je pre svega simptomatska, te se kao prvi lek najčešće upotrebljava simetikon u različitim dozama. Prema rezultatima pojedinih studija povoljan efekat na smanjenje nadimanja trbuha imaju i spazmolitici, kao što su pinaverin, mebeverin, otilonijum bromid, pepermintovo ulje, delujući na visceralnu hipersenzitivnost ovih pacijenata. Ukoliko kod pacijenata dominiraju simptomi opstipacije, u terapiji se primenjuju lekovi u zavisnosti od težine tegoba. Mogu se primeniti laksativi, ali i prokinetici, kao što je prukaloprid, ili sekretagogi, kao što su linaklotid, lubiproston, plekanatid. Akotiamid, inhibitor acetilholin esteraze i antagonista muskarinskih receptora, pokazao je pozitivno dejstvo na nadimanje, u studijama japanskih autora. Prema rezultatima studija veliki značaj u terapiji nadimanja i distenzije trbuha ima lokalni antibiotik rifaksimin. Rifaksimin ima minimalnu resorpciju iz kolona, pogodan je posebno kada se kod pacijenta postavi dijagnoza SIBO, dozira se tri puta 550mg, u trajanju od 14 dana. Uloga probiotika i dalje je intrigantna, obzirom da značajnu ulogu u patogenezi nadimanja ima izmenjena crevna mikrobiota. Sa druge strane nasumična primena probiotika mogla bi da poremeti sastav crevne mikrobiote, te se očekuje u budućnosti personalizovana primena probiotika na osnovu analize crevne mikrobiote svakog pacijenta pojedinačno. Do tada preporučuje se primena sojeva VSL#3, Lactobacillusa i Bifidobacteriuma. Primena neuromodulatora, takođe, ima veliki značaj i primenjuje se kada sve ostale terapije ne daju povoljne rezultate. Ovi lekovi uključuju inhibitore preuzimanja serotonina, triciklične antidepressive, buspirone. Na kraju treba napomenuti da se u terapiji nadimanja koriste i biljna terapija kao što je kurkumin, komorač, ali i lekovi tradicionalne kineske i japanske medicine.
- 1 June 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (6) , 152945
Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy
- 1 June 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (6) , 152945
Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy
- 27 August 2015
- Published by Wiley in Journal of Digestive Diseases
- Vol. 16 (12) , 723-733
Variations in inflammatory genes as molecular markers for prediction of inflammatory bowel disease occurrence
Objective Research on inflammatory bowel disease (IBD) has highlighted genes involved in the regulation of inflammatory responses as contributors to disease pathogenesis. This study aimed to evaluate the associations between IBD and variations in NOD2, TLR4, TNF‐α, IL‐6, IL‐1β and IL‐1RN genes, and to use the genetic data obtained in predictive modeling. Methods A total of 167 IBD patients and 101 healthy controls were genotyped by polymerase chain reaction‐restriction fragment length polymorphism. Using the genotype data attained as the input to various classification algorithms, IBD prediction models were designed. The area under the receiver operating characteristic curve (AUROC) was used to measure their performance. Results Significant associations were found between Crohn's disease (CD) and minor NOD2 variants, as well as TLR4 299Gly, TNF‐α G‐308A, IL‐6 G‐174C and IL‐1RN VNTR A2 variants, while ulcerative colitis (UC) was associated only with IL‐1RN VNTR A2 variants. CD and UC showed highly significant difference in the allelic distribution of TNF‐α G‐308A, where the A allele was found to be related to CD, and the G allele to UC. A combined effect of patients' gender and TLR4 variants was observed among CD patients. When all analyzed genotype and gender data were used, prediction performance achieved a maximum AUROC of 0.690 for CD and 0.601 for UC dataset. Conclusion Variations in the genes involved in immune regulation are genetic factors of importance in IBD susceptibility that could potentially be used as predictors of disease development.
- 27 August 2015
- Published by Wiley in Journal of Digestive Diseases
- Vol. 16 (12) , 723-733
Variations in inflammatory genes as molecular markers for prediction of inflammatory bowel disease occurrence
Objective Research on inflammatory bowel disease (IBD) has highlighted genes involved in the regulation of inflammatory responses as contributors to disease pathogenesis. This study aimed to evaluate the associations between IBD and variations in NOD2, TLR4, TNF‐α, IL‐6, IL‐1β and IL‐1RN genes, and to use the genetic data obtained in predictive modeling. Methods A total of 167 IBD patients and 101 healthy controls were genotyped by polymerase chain reaction‐restriction fragment length polymorphism. Using the genotype data attained as the input to various classification algorithms, IBD prediction models were designed. The area under the receiver operating characteristic curve (AUROC) was used to measure their performance. Results Significant associations were found between Crohn's disease (CD) and minor NOD2 variants, as well as TLR4 299Gly, TNF‐α G‐308A, IL‐6 G‐174C and IL‐1RN VNTR A2 variants, while ulcerative colitis (UC) was associated only with IL‐1RN VNTR A2 variants. CD and UC showed highly significant difference in the allelic distribution of TNF‐α G‐308A, where the A allele was found to be related to CD, and the G allele to UC. A combined effect of patients' gender and TLR4 variants was observed among CD patients. When all analyzed genotype and gender data were used, prediction performance achieved a maximum AUROC of 0.690 for CD and 0.601 for UC dataset. Conclusion Variations in the genes involved in immune regulation are genetic factors of importance in IBD susceptibility that could potentially be used as predictors of disease development.